Tag: cardiovascular mortality
-
Uloric Recall, “Black-Box Warning”, And Limited Use Discussed By FDA Advisory Committees In January 2019
Despite Drug Safety Problem Of Cardiovascular Mortality, Benefits Might Be Seen To Outweigh Risks For Select Gout Patients (Posted by Tom Lamb at DrugInjuryWatch.com) Uloric (febuxostat) was approved by the FDA in…
-
Benicar Cardiovascular-Related Deaths: FDA Safety Review Which Started In June 2010 Is Still Ongoing In August 2013
When Will Daiichi Sankyo And FDA Report On Additional Studies And Analyses Of Clinical Studies About Cardiovascular Mortality Increased Risks Of Benicar (Posted by Tom Lamb at DrugInjuryWatch.com) In June 2010 the FDA issued…